CV Sciences, Inc. (OTCQB:CVSI) plans to publish its financial results for the third quarter ended September 30, 2026, after the stock market closes on Thursday, November 12, 2026. The company will discuss the results with the investment community during a conference call later that day.
The conference call is scheduled to begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Investors in the U.S. can join by calling (844) 825-9789, while international participants can use (412) 317-5180.
CV Sciences has asked callers to connect 15 minutes before the start of the call because of increased demand for conference calls.
The event will be webcast through the Investor Relations section of CV Sciences' website. The webcast will remain archived for approximately 30 days.
A telephone replay is expected to become available approximately two hours after the conference call ends. It will remain accessible through Thursday, November 26, 2026. The U.S. replay number is (844) 512-2921, and international callers can dial (412) 317-6671. Participants will need confirmation code 10212857.
CV Sciences is a consumer wellness company focused on nutraceuticals, plant-based foods, hemp extracts and other science-backed natural ingredients and products. Its products are sold through business-to-business and business-to-consumer channels.
The company's portfolio includes +PlusCBD™ hemp-extract products, +PlusHLTH™ non-cannabinoid supplements and Cultured Foods™ 100% plant-based food products. CV Sciences also owns Elevated Softgels, which manufactures encapsulated softgels and tinctures for the supplement and nutrition industry.
CV Sciences has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. Cultured Foods™ products are distributed primarily in the EU and other select markets.
CV Sciences, Inc. announced that it will release its financial results for the third quarter ended September 30, 2026, after the stock market closes on Thursday, November 12, 2026. The company will also hold a conference call with the investment community on the same day.
CV Sciences, Inc. will release its financial results for the third quarter ended September 30, 2026, after the stock market closes on Thursday, November 12, 2026.
CV Sciences, Inc. will hold its conference call on Thursday, November 12, 2026, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Investors can join the live call by dialling (844) 825-9789 from the U.S. or (412) 317-5180 from international locations. CV Sciences, Inc. asks participants to dial 15 minutes before the start time due to increased demand for conference calls.
The webcast will be available through the Investor Relations section of CV Sciences, Inc.'s website at https://ir.cvsciences.com/news-events or directly at https://viavid.webcasts.com/starthere.jsp?ei=1779873&tp_key=be4c149620.
The webcast of CV Sciences, Inc.'s conference call will be archived for approximately 30 days.
The telephone replay will be available approximately two hours after the call concludes and will remain available through Thursday, November 26, 2026.
The replay can be accessed by dialling (844) 512-2921 from the U.S. or (412) 317-6671 from international locations and entering confirmation code 10212857.
CV Sciences, Inc. is a consumer wellness company specialising in nutraceuticals and plant-based foods. Its hemp extracts and other science-backed natural ingredients and products are sold through sales channels ranging from B2B to B2C.
CV Sciences, Inc.'s brands include +PlusCBD™ hemp-extract products, +PlusHLTH™ non-cannabinoid supplements and Cultured Foods™ 100% plant-based food products. The company also owns Elevated Softgels, which manufactures encapsulated softgels and tinctures for the supplement and nutrition industry.
CV Sciences, Inc. is identified in the announcement as trading on the OTCQB under the ticker symbol OTCQB:CVSI.
CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. Its Cultured Foods™ products are distributed primarily in the EU and other select markets.